Susquehanna Fundamental Investments’s Neurocrine Biosciences NBIX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-114,661	Closed	-$15.7M	–	1175
2024 Q4	$15.7M	Buy	+114,661	New	+$14.2M	0.22%	110
2024 Q2	$509K	Buy	+3,695	New	+$507K	0.01%	688
2021 Q4	–	Sell	-47,618	Closed	-$4.57M	–	1659
2021 Q3	$4.57M	Buy	47,618 +40,168	+539%	+$3.79M	0.08%	317
2021 Q2	$725K	Sell	7,450 -13,966	-65%	-$1.34M	0.01%	1006
2021 Q1	$2.08M	Sell	21,416 -396	-2%	-$41.5K	0.04%	630
2020 Q4	$2.09M	Buy	+21,812	New	+$2.11M	0.04%	607

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Susquehanna Fundamental Investments's NBIX Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 114,661 shares — an estimated $15.7M sold.

Susquehanna Fundamental Investments first reported a position in NBIX in Q4 2020 and held it in 6 quarters. The position peaked at $15.7M in Q4 2024. 587 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

Susquehanna Fundamental Investments reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 114,661 Neurocrine Biosciences shares in Q1 2025, an estimated $15.7M.
Susquehanna Fundamental Investments first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 6 quarters.
Susquehanna Fundamental Investments's Neurocrine Biosciences position peaked at $15.7M in Q4 2024.
587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.